Drug Information Association Logo
« Back to Listing

Unraveling Evidence-Based Medicine: A Scientific, Ethical, and Socio-Political Analysis

Track:
Comparative Effectiveness Research/Global Health Outcomes and Economics

Day & Time:
June 17, 1:30PM - 3:00PM (Pacific Standard Time)

Session Number:
274

Room Number:
9

Level:
Basic

Type:
Forum

Title:
Unraveling Evidence-Based Medicine: A Scientific, Ethical, and Socio-Political Analysis

Chair(s):
Christopher M. Marrone, PharmD
Outcomes Liaison
Eli Lilly and Company, United States

Description:
There is concern worldwide about rising health costs and shrinking health budgets, and it is now broadly accepted that we must all apply the best alternatives in medical treatment. But disagreement persists as to what methods are acceptable for comparing treatments, and whether they are ethically, politically, and commercially sound. Some of the scientific and ethical questions will be addressed in this important cross-discipline community dialogue.

This forum has been developed by the DIA Evidence Based Medicine Community, the DIA Ethics and the Medicines Lifecycle Community, and the Comparative Effectiveness Scientific Working Group.

Learning Objective(s):
Define evidence-based medicine; Explain the shift towards comparative effectiveness research; Discuss the key ethical, socio-political, and commercial implications of this shift.

Presentation(s) & Speaker(s):
Panelist
Wendy Louise Lipworth, MD, PhD
Senior Research Fellow, Centre for Values, Ethics and the Law in Medicine
University of Sydney, Australia

Panelist
Kitty Rajagopalan, PhD, MS
Vice President, Health Economics and Outcomes Research
Sunovion Pharmaceuticals Inc., United States

Panelist
Lisa M. Hess, PhD
Principal Research Scientist, US Health Outcomes
Eli Lilly and Company, United States